PHVS: Pharvaris Corp Price to Sales
The primary driver for Pharvaris N.V. (PHVS) will be the market launch of oral treatments for hereditary angioedema. The price-to-sales multiple visualizes investor expectations, where the value represents the current metric. Profit potential is linked to replacing injections with tablets for HAE patients. Furthermore, the focus on proprietary internal development makes the company an attractive acquisition target for corporate behemoths.
Metric breakdowns and analytics for Pharvaris Corp (PHVS)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Pharvaris N.V.|PHVS - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Pharvaris Pharma|PHVS - Company Total Debt|Debt to Book Capitalization Ratio Pharvaris Corp|PHVS - Company Long-Term Debts|Company Short-Term Debts Pharvaris|Intermediate Coverage Ratio pharvaris.com
- earnings and valuation multiples indicators:
PHVS - Net Profit|Company Profit Forecast Pharvaris N.V.|PHVS - Price to Earnings Ratio|Market Cap to Projected Earnings Pharvaris NV|PHVS - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Pharvaris Corp|PHVS - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Pharvaris|PHVS - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months pharvaris.com|PHVS - Net earnings per share growth this year|Net earnings per share growth forecast for next year Pharvaris N.V.
- issuer revenue and sales details:
Summary company analytics:pharvaris.com PHVS
The implementation of AI and automated compound synthesis systems at Pharvaris N.V. (PHVS) is accelerating preclinical testing, directly impacting the potential of future cash flows. By analyzing the historical P/S chart, an investor assesses the market value of the business through the ratio of market capitalization to total revenue, where a stable trend confirms sales resilience, while sharp deviations signal overvaluation or hidden reporting risks.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Sales Ratio PTGX|IMVT: P/S Multiple|kiniksa.com - Market Capitalization-to-Revenue Ratio|GRFS (Grifols) - P/S Multiple|P/S Multiple Adaptive Biotech|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|BioCryst - Market Cap to Revenue|veratx.com - Price-to-Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|ABCL - P/S Multiple|Tourmaline Corp (TRML) - Price-to-Revenue Ratio|Precigen Corp - Market Capitalization-to-Revenue Ratio|PHAR (Pharming Group N.V.) - P/S Multiple|nektar.com (NKTR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Upstream Bio (UPB)|Price-to-Revenue Coefficient Zenas Bio|Immunome Corp - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio GOSS|KALV - Price-to-Revenue Ratio|SEPN (septerna.com) - Market Cap to Revenue Ratio|PVLA (Pieris Pharmaceuticals, Inc.) - Market Cap to Revenue|SVRA - Price-to-Revenue Coefficient|Market Cap to Revenue RIGL|Price-to-Revenue Ratio ANAB|Market Cap to Revenue ATXS (Astria Therapeutics)|Price-to-Revenue Coefficient engene.com|Price-to-Revenue Ratio RAPT Therapeutics RAPT|JBIO (Aerovate Therapeutics, Inc.) - Price-to-Sales Ratio|Aclaris - P/S Multiple|Market Capitalization-to-Revenue Ratio KYTX (Kyverna Therapeutics, Inc)|TLSA (Tiziana Life Sciences) - Market Cap to Revenue|CABA (cabalettabio.com) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Ventyx Biosciences, Inc.|Theratechnologies, Inc. (THTX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|ELDN: Price-to-Sales Ratio|P/S Multiple AGEN (Agenus)|Market Capitalization-to-Revenue Ratio CLYM|Zura Bio - P/S Multiple|ATYR - P/S Multiple|adagene.com (ADAG) - Price-to-Revenue Ratio|Ikena Oncology - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Shattuck Labs Inc|Market Cap to Revenue Equillium Bio (EQ)|P/S Multiple CNTB|P/S Multiple immunic-therapeutics.com (IMUX)|Atara Bio - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IFRX|X4 Pharmaceuticals - P/S Multiple|Price-to-Revenue Coefficient Adicet Bio ACET|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue INmune Bio Inc|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|Market Cap to Revenue SABS (SAB Biotherapeutics)|P/S Multiple akaritx.com (AKTX)|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB: Market Cap to Revenue Ratio|GeoVax Labs Inc - P/S Multiple|Price to Sales Edesa Biotech Corp|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Price-to-Sales Ratio CARM (Carisma Therapeutics Inc.)|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|BOLT: Market Capitalization-to-Revenue Ratio|P/S Multiple HCWB|P/S Multiple aptevotherapeutics.com (APVO)|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI: Market Cap to Revenue|XRTX: Price-to-Revenue Ratio|HIND: P/S Multiple|Revelation Biosciences Corp (REVB) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|SCNI: Market Capitalization-to-Revenue Ratio|P/S Multiple CALI|Price-to-Revenue Coefficient affimed.com|Price-to-Revenue Ratio Allakos ALLK|Price-to-Revenue Coefficient HOOKIPA Pharma, Inc. (HOOK)|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iteostherapeutics.com)|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TCBP|Market Cap to Revenue THRD
